Evidence map›Paper›PMID 41054563›Full record

ArticlePeerJ2025

Novel monoclonal antibodies for immunodetection of AmpC β-lactamases.

Karolina Bielskė, Martynas Simanavičius, Julie Nuttens, Julija Armalytė, Justas Dapkūnas, Lukas Valančauskas, Aurelija Žvirblienė

Abstract read
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karolina BielskėInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.ORCID 0009-0000-3768-9401
Martynas SimanavičiusInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.ORCID 0000-0003-2996-229X
Julie NuttensArcDia International Ltd, Turku, Finland.
Julija ArmalytėInstitute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania.ORCID 0000-0003-0986-9805
Justas DapkūnasInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.ORCID 0000-0002-0496-6107
Lukas ValančauskasInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Aurelija ŽvirblienėInstitute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accurate and easy-to-perform assays for the detection of antibiotic-resistant bacterial isolates producing AmpC β-lactamases are epidemiologically relevant, leading to more effective use of antibiotics and a comprehensive understanding of β-lactamase prevalence. We describe novel monoclonal antibodies (MAbs) against CMY β-lactamases and their application in immunoassays for the detection of CMY-producing bacterial isolates. Methods: Recombinant CMY-34 was expressed in Results: Two high-affinity MAbs raised against recombinant CMY-34 were characterized in detail. Both MAbs recognized CMY-34 β-lactamase in the Conclusion: Novel MAbs raised against CMY-34 recognize common epitopes of CMY β-lactamases and can be applied for immunodetection of CMY β-lactamases in bacterial isolates.

Indexed as

Antibodies, MonoclonalBacterial Proteinsbeta-LactamasesAnimalsEnzyme-Linked Immunosorbent AssayEpitopesEscherichia coliHumansImmunoassayMiceRecombinant ProteinsAmpC beta-lactamasesAntibodies, MonoclonalBacterial Proteinsbeta-LactamasesEpitopesRecombinant ProteinsCMY-34CMY β-lactamasesELISALateral flow immunoassayMonoclonal antibodiesTPX assayβ-lactamase detection

Identifiers

PMID41054563
PMCPMC12497404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.